The emergence of regenerative medicine created a paradigm shift in how we approach cardiovascular diseases. This innovation has required a careful evaluation of the interaction between the recipient myocardium and the stem cells at the most fundamental cellular and molecular levels. The Stanford Cardiovascular Stem Cell Laboratory laboratory directed by Phillip C. Yang, MD is advancing cellular and molecular approaches to regenerate the diseased myocardium through precision medicine and personalized therapeutics. Novel autologous iPSC derivatives including, exosomes, proteomes, and small molecules are investigated employing advanced imaging technology.
Dr. Yang has also focused on advancing the translation of iPSC-derived cardiomyocytes (iCMs) and investigating their therapeutic potential. He is a PI on NIH/NHLBI funded Cardiovascular Cell Therapy Research Network (CCTRN) UM1 grant, which is designed to conduct multi-center clinical trial on novel stem cell therapy. In addition, he is a PI on 2 NIH, and 3 industry-sponsored research study or clinical trial grants. He received prior funding from CIRM, AHA, NIH K23, NIH K18, and NIHR01 to develop and translate novel stem cell biology, employing advanced in vivo imaging tools. Dr. Yang also directs the Stanford Cardiovascular MRI Program.